Blood Cancer United-led master clinical trial has provided genomic analysis to more than 2,000 patients and advanced treatment approaches from early studies into phase 3 research.
WASHINGTON, November 17, 2026 – Blood Cancer United® today marked the 10th anniversary of its Beat AML® Master Clinical Trial, the first collaborative precision medicine clinical trial in a blood cancer.
Blood Cancer United launched Beat AML in 2016 to challenge the one-size-fits-all approach that had long defined acute myeloid leukemia, or AML, treatment. The trial uses advanced genomic technology to identify the genetic changes driving each patient’s AML and match eligible patients to treatment sub-studies based on the biology of their disease.
Since its launch, more than 2,000 patients have participated in the Beat AML master protocol, receiving genomic analysis to help inform their treatment options. In addition, more than 720 patients have enrolled across 17 clinical sub-studies, evaluating investigational treatments in collaboration with pharmaceutical and biotechnology companies. Beat AML findings have contributed to 65 publications and abstracts.
“Beat AML began with a bold scientific question: Could we rapidly understand the biology of each patient’s AML and use that information to guide precision treatment?” said E. Anders Kolb, M.D., president and CEO of Blood Cancer United. “Today, we know that advanced diagnostics not only guide treatment but also improve outcomes. With that foundation, Beat AML united patients, researchers, clinicians, and industry partners around a shared goal. Together, we have built a master clinical trial that has evolved with the state-of-the-art, accelerated the study of promising treatments, and helped create more time and better outcomes for people with AML.”
Meeting the urgent need for better AML treatments
An estimated 22,700 people in the United States will be diagnosed with AML in 2026. It is one of the most aggressive blood cancers and is difficult to treat because it includes biologically distinct subtypes and rare genetic mutations that may respond differently to treatment.
Approximately 1 in 3 people living with AML survive five years after diagnosis, and incidence begins to increase notably among people age 55 and older. Many older patients cannot tolerate intensive chemotherapy, while patients whose disease returns or stops responding to treatment have limited options.
Blood Cancer United initially designed Beat AML for adults age 60 and older with newly diagnosed AML. With genomic analysis provided by Foundation Medicine, the trial set out to complete comprehensive genomic and cytogenomic analysis and assign treatment within seven days. Findings published in Nature Medicine in 2020 showed that Beat AML achieved that primary endpoint for 94.7% of eligible patients. Further, patients who enrolled in Beat AML sub-studies also had longer overall survival than those who received standard treatment.
Beat AML demonstrated that it’s feasible to quickly gather comprehensive genomic information to determine targeted treatment options for AML. This remains foundational today since genomic testing plays an increasingly important role in treating this fast-moving, aggressive cancer.
Beat AML’s impact over the past decade
Beat AML brings together academic investigators, treatment centers, genomic experts, pharmaceutical and biotechnology companies, data specialists, and clinical research organizations through shared infrastructure that can adapt as the science evolves.
Over the past decade, Beat AML has expanded its scientific impact for people with AML by:
- Establishing a master-trial that could be modeled: Beat AML demonstrated how a nonprofit-led master clinical trial could integrate genomic screening, multiple treatment sub-studies and a broad network of research collaborators. In 2021, Beat AML researchers and operational partners published lessons in a peer-reviewed journal that provided insights for other organizations to model when developing master trials. In 2022, Blood Cancer United launched PedAL, extending the precision medicine master-trial approach to pediatric acute leukemia.
- Expanding the breadth of clinical research: Beat AML now spans phase 1b, phase 2 and phase 3 research, allowing multiple sub-studies to evaluate targeted therapies and treatment combinations for different forms of AML. Originally focused on adults age 60 and older with newly diagnosed AML, Beat AML now includes patients age 18 and older, patients with myelodysplastic syndrome (MDS), and relapsed/refractory AML or MDS.
- Answering questions arising in patient care: Recent results published in Blood for the OPTI-AML sub-study provided new information about whether some older patients with newly diagnosed AML could receive a shorter schedule of venetoclax when it is given with azacitidine. The study was important since venetoclax schedules are often shortened in clinical practice because of side effects. The study found that the optimal duration of venetoclax varies by AML genetic mutation, reinforcing the need to tailor treatment based on disease biology.
- Moving promising approaches into registration-directed clinical studies: Evidence generated through Beat AML has supported the progression of an investigational menin inhibitor combination from phase 1b research into phase 3 evaluation (see below details for BAML-16-001-S17 and BAML-16-001-S26).
Leading the next phase of AML treatment
Beat AML’s active portfolio spans the clinical development continuum, from early-stage studies of new treatment combinations to phase 3 trials. Internationally, Beat AML and its investigators are participating in global phase 3 studies sponsored by HOVON, a non-profit foundation located in The Netherlands.
Following are the current active substudies of Beat AML:
| Study or program | Details |
BAML-16-001-S17 Phase 1b dose escalation and expansion
(Enrollment complete) | Revumenib with azacitidine and venetoclax in adults with newly diagnosed AML with NPM1 mutations or KMT2A rearrangements who were not eligible for intensive chemotherapy. Findings supported continued evaluation of the combination in phase 3 research. Read the phase 1b results in the Journal of Clinical Oncology. |
BAML-16-001-S24 Phase 1b safety run-in/Phase 2
(Actively recruiting) | Ficlatuzumab with azacitidine and venetoclax in adults with newly diagnosed AML across molecular subtypes. |
BAML-16-001-S25/HO181 Phase 3
(Actively recruiting) | Bleximenib with standard induction and consolidation chemotherapy, in adults with newly diagnosed AML with NPM1 mutations or KMT2A rearrangements who are eligible for intensive chemotherapy. |
BAML-16-001-S26/HO177 Phase 3
(Actively recruiting) | Revumenib with azacitidine and venetoclax in adults with newly diagnosed AML with NPM1 mutations or KMT2A rearrangements who are not eligible for intensive chemotherapy. |
“It has taken nearly a decade to build the science and infrastructure needed to support potentially practice-changing studies,” said Alice Mims, M.D., Beat AML chief medical officer and a hematologist at The Ohio State University Comprehensive Cancer Center. “As Beat AML enters its second decade, we have an opportunity to build on that foundation by answering important treatment questions, evaluating new approaches and bringing clinical trials closer to patients. Our goal is to generate evidence that helps people with AML and their physicians make more informed treatment decisions and, ultimately, live longer, fuller lives.”
Beat AML research at ASH 2026
Beat AML investigators will present three oral abstracts and three posters at the 2026 American Society of Hematology Annual Meeting and Exposition from Dec. 12-15, 2026, in New Orleans.
A key oral presentation will include updated results from a Phase 1b trial of revumenib in combination with venetoclax and azacitidine in newly diagnosed patients with NPM1-mutated or KMT2A-rearranged AML. These findings support the ongoing randomized phase 3 study, BAML-16-001-S26/HO177, which is mentioned above. (Oral presentation; Abstract 662).
Four presentations will feature findings from OPTI-AML, the Beat AML sub-study comparing 14-day and 28-day courses of venetoclax in combination with azacitidine in older adults with newly diagnosed acute myeloid leukemia. Findings include:
- Genotype-specific molecular dynamics and molecular tumor load can help guide treatment intensity selection. (Oral presentation; Abstract 389)
- Existing timing guidance for hematologic recovery (return to normal blood counts) may underrecognize meaningful long-term responses. (Oral presentation; Abstract 897)
- A baseline for future studies of wearable devices to help address whether remote monitoring is beneficial in an age of decentralized trials. (Poster presentation; Abstract 4600)
- Prognostic Risk Integration for Survival Modeling (PRISM), a recently developed risk model, has potential use for risk stratification in clinical trials to identify patients who may benefit from new treatment approaches. (Poster presentation; Abstract 3476)
A sixth presentation is a retrospective analysis of data in a cohort of Beat AML patients with myeloproliferative neoplasms (MPN), which underscores the need for continued development of novel approaches and trials inclusive of this high-risk population. (Poster presentation; Abstract 3794)
Blood Cancer United proudly and gratefully acknowledges the Kellenyi family for their generous donation in memory of John Kellenyi, and the Harry T. Mangurian, Jr. Foundation for its philanthropy in honor of Harry T. Mangurian, Jr.
About Blood Cancer United®
Blood Cancer United® (formerly The Leukemia & Lymphoma Society) is the largest global nonprofit focused on blood cancer patient support, research and advocacy. The organization’s mission is to cure blood cancer and improve the quality of life of all patients and their families. To achieve it, Blood Cancer United brings together a community of patients and their families, volunteers, health care providers, scientists, staff, partners, fundraisers and philanthropists who believe all people with blood cancer deserve longer, fuller lives. For support and to learn more, visit Blood Cancer United.
About Beat AML®
The Beat AML® Master Clinical Trial (NCT03013998), launched in 2016 by Blood Cancer United, is the first collaborative precision medicine clinical trial in a blood cancer. The trial uses advanced genomic technology to match eligible patients with promising targeted treatments based on the unique genetic mutations driving their disease.
Beat AML evaluates multiple therapies simultaneously through multiple clinical sub-studies. The trial has generated results showing improved survival and quality of life among patients who received treatment matched to the molecular characteristics of their cancer. Over the past decade, Beat AML has grown into a powerful research ecosystem that brings together pharmaceutical and biotechnology companies, genomic testing experts, data specialists, regulatory agencies, treatment centers and other collaborators working to develop better, safer treatments for people with acute myeloid leukemia.
For more information, visit Beat AML.
Media contact:
Sandra Salviejo
Senior Director, communications
[email protected]